Vaughn, Caila B. http://orcid.org/0000-0001-8155-3501
Jakimovski, Dejan http://orcid.org/0000-0001-7114-4958
Kavak, Katelyn S.
Ramanathan, Murali
Benedict, Ralph H. B.
Zivadinov, Robert
Weinstock-Guttman, Bianca http://orcid.org/0000-0001-6732-151X
Article History
First Online: 18 April 2019
Competing interests
: C.B.V. declares that she has received consultancy fees from Merck/EMD Serono. M.R. declares that he has received research funding from the US National Institute of Neurological Disorders and Stroke and the US National Science Foundation. R.H.B.B. declares that he has received research support from Accorda, Biogen, Genzyme, Mallinckrodt and Novartis; consultancy fees from Biogen, Genentech, Genzyme, Novartis, Roche, Sanofi and Teva; and compensation for activities relating to continuing medical education from EMD Serono. R.Z. declares that he has received speakers’ and consultancy fees from Celgene, Claret Medical, EMD Serono, Genzyme-Sanofi, IMS Health, Novartis and Roche-Genentech and financial research support from Claret Medical, IMS Health, Intekrin, Genzyme-Sanofi and Novartis. B.W.-G. declares that she has received fees for consultancy, acting as a speaker and serving on the scientific advisory boards of Biogen Idec, EMD Serono, Genzyme-Sanofi, Novartis, Questcor and Teva Neuroscience, and financial research support from Aspreva, Biogen Idec, EMD Serono, Genzyme, the Immune Tolerance Network Clinical Trials Group, the National Multiple Sclerosis Society, the NIH (not related to the present work), Novartis and Teva Neuroscience. D.J. and K.S.K. declare no competing interests.